May. 27 at 7:55 AM
$ZVRA We have quite a few peeps here, who want nothing more than to “go on, take the money and run 🎶 .” I’ve been here 6 years to date, still patiently waiting. For those who’ve been here less, sorry, but my heart does not go out to you.
Celiprolol could eventually add
$300M –
$500M+ in annual revenue at peak, making it potentially larger than Miplyffa. Combined with Miplyffa (US + Europe), Zevra could theoretically reach
$500M –
$800M+ in total annual revenue by 2030–2031 if both drugs succeed.
Am I saying that everything will go perfectly and the above will “absolutely” happen? No. Am I saying that Zevra should pass up an opportunity to sell now? No. But for those shouting that Zevra’s fare marker value is currently sitting at
$700M (
$1B minus current cash-on-hand, or
$20 per share), I say… no. You are looking at Zevra’s massively suppressed share price and falling right into the exact gullible trap that they want you to believe, that this is currently only a
$10 stock.
